Late Breaking News
WASHINGTON, DC—The hepatitis C (HCV) treatment program in VA marks its 10-year anniversary this year on a note of hopeful expectation. For years the only treatment for HCV has been combination pegylated interferon and ribavirin—a treatment with harsh side effects and a cure rate between 20% and 25% among VA patients. But several new drugs currently in development promise to almost double that success rate, which is good news for VA’s 150,000 HCV patients.
WASHINGTON, DC—Over the last several years, federal agencies have made a concerted effort to direct research and funding to those rare diseases that might not get attention if left to the whim of market forces. For rare pediatric diseases, the challenge can be even greater.
Most Popular Stories
- Many Healthcare Providers Lose VA Retention Bonuses
- Federal Medicine Organizational Meetings — Tarred with the Same Brush?
- Despite Formulary, High-Cost Diabetes Drug Use Varies Widely Across VA Facilities
- Report Says Administration Faces Hard Choices For Veterans Programs
- Physician Overcomes TBI to Return to Active-Duty Medicine
Join Our E-Mail List